Cell and Gene Therapy: Transforming Treatment Paradigms for Patient-Centric Care

Area of Science:

• Pharmacology and Therapeutics
• Biotechnology
• Genetics

Background:

• Cell and gene therapies (CGTs) are revolutionizing medicine with potential cures for intractable diseases.
• Significant challenges persist, including optimizing efficacy, safety, patient accessibility, and managing high costs, especially for rare conditions.

Purpose of the Study:

• To summarize key discussions from the 2025 ASCPT CGT satellite conference on transforming treatment paradigms for patient-centric care.
• To provide insights into gene therapies and T-cell immunotherapies from scientific, clinical, and patient viewpoints.

Main Methods:

• Review of presentations and discussions from the ASCPT 2025 CGT satellite conference.
• Synthesis of information on gene therapy platforms, adeno-associated virus (AAV) gene therapy for hemophilia, clinical pharmacology, and model-informed drug development (MIDD).
• Analysis of T-cell immunotherapies, including CAR T-cell therapy, allogeneic CAR T, and MIDD strategies.

Main Results:

• Gene therapy advancements include 'platformization' for streamlined development and lessons from AAV-based hemophilia therapies.
• T-cell immunotherapies like CAR T therapy show promise, with focus on kinetics, efficacy, safety, and emerging allogeneic approaches for autoimmune diseases.
• Model-informed drug development (MIDD) is crucial for optimizing therapy design and clinical outcomes in both gene and T-cell therapies.

Conclusions:

• CGTs hold immense therapeutic potential, but overcoming challenges in development, cost, and accessibility is vital for patient-centric care.
• Continued research and application of strategies like platformization and MIDD are essential for advancing CGT efficacy and safety.
• The conference highlighted the need for integrated scientific, clinical, and patient perspectives to fully realize the transformative power of CGTs.